CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Assess response to pembrolizumab in both primary tumor, normal breast stroma, circulating lymphocytes and serum exosomes in treatme ...
Phase 1
Maywood, Illinois, United States and 2 other locations
This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 o...
Phase 2
Chicago, Illinois, United States and 6 other locations
This research study is for patients with metastatic breast cancer.* Metastatic means that the cancer has spread beyond the ...
Phase 2
Chicago, Illinois, United States and 19 other locations
This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast...
Phase 2
Chicago, Illinois, United States and 6 other locations
participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast...
Phase 1, Phase 2
Chicago, Illinois, United States and 22 other locations
This research study is studying a combination of drugs as a possible treatment for breast cancer.The drugs involved in this study a...
Phase 2
Chicago, Illinois, United States and 16 other locations
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd...
Phase 2
Chicago, Illinois, United States and 62 other locations
to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast...
Phase 3
Chicago, Illinois, United States and 117 other locations
postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an acquired ESR1 mutation and who have diseas...
Phase 2
Chicago, Illinois, United States and 50 other locations
The human epidermal growth factor receptor 2 (HER2) regulates cell growth and survival. Approximately 15-20% of all breast cancers ...
Phase 1, Phase 2
Chicago, Illinois, United States and 6 other locations
Clinical trials
Research sites
Resources
Legal